Hinova (688302.SH) is an international and clinical-stage pharmaceutical company focused on developing new therapeutics for cancers and metabolic syndromes through PROTAC and deuteration technology. We are committed to the discovery and development of innovative drugs with global interests that meet the significant clinical needs.

Hinova pharma has 4 core R&D platforms, which are PROTAC (PROteolysis Targeting Chimera) platform, deuteration platform, novel target discovery and validation platform, and lead compound optimization screening platform. We have submitted more than 200 PCT and national patents, with more than 60 patents granted in China and in the globe, such as the US, EU, and Japan. We have 10 innovative projects in the R&D stage, and 2 National Major Projects of “Significant New Drugs Creation “awarded by Ministry of Science and Technology of the People’s Republic of China. The company is led by a management team comprised of accomplished experts in the biotechnology and pharmaceutical industries. The core team members are mostly from the world's Top 500 pharmaceutical companies, with 2 national-level and several provincial-level experts.

Among the pipeline and programs, HC-1119 has entered the global multicenter phase-III clinical trials for the treatment of castration-resistant prostate cancer. HP501 for the treatment of hyperuricemia and gout, the Phase-II clinical trial of which has been completed in China. The Phase-II clinical trial of HP558 which is potenially effective for esophageal cancer, has been approved by NMPA. HP518, an orally bioavailable chimeric degrader targeting AR, is in Phase-I clinical trials in Australia.